Introduction {#Sec1}
============

One of the major challenges in oncology is a correct prediction of individual recurrence risk and the prediction of efficacy and safety of therapy. Histopathology is only partly able to mirror and predict the clinical behaviour of individual tumours. Through the application of molecular tools, otherwise indistinguishable tumour subgroups have been identified and the definition of a precise gene mutation pattern has highlighted classes of tumours with clinical prognostic implications \[[@CR1]\]. Moreover the application of molecular tests such as real time PCR based assays has become feasible thanks to the use of formalin-fixed paraffin embedded samples \[[@CR2]\], which represent the most valuable source of diagnostic materials. As a consequence, in the near future molecular approaches in formalin fixed and paraffin embedded (FFPE) material will become part of the routine process of cancer diagnostics. At the present time most of the methods applied in molecular pathology are laboratory-based assays and commercial kits not directly intended for diagnostic purposes. Therefore there is a need to establish guidelines with standardised procedures for molecular methods, starting from an analysis of the currently used methods of nucleic acids extraction.

This collaborative study includes 13 European laboratories of the IMPACTS group ([www.impactsnetwork.eu](http://www.impactsnetwork.eu)) and was conducted to evaluate the performance of nucleic acids extractions using the same formalin-fixed paraffin-embedded specimens. The aim of the study is to assess if the different methodologies used for nucleic acids extraction in different laboratories might affect the results.

Materials and methods {#Sec2}
=====================

Four cases of formalin-fixed paraffin-embedded tissues were distributed to the participants in the study in two rounds. In detail, the Trieste group delivered one colorectal cancer specimen during the first control round. The Berlin group delivered an ovary cancer sample and the Graz group delivered two lung cancer cases in the second control round. Surgical specimens with a large amount of tissue were used to ensure to have sufficient material for the multicentre analysis. Comparable tissue areas distributed in 2 to 4 sections of 5 μm in thickness were used per test and distinct tissue blocks of the same cases were selected for RNA and DNA extractions. The sections were collected sequentially: each following section was given to a different participant in order to obtain the most homogeneous representative tissues in all the different laboratory tests. Tissue slides were sent under vacuum at room temperature. The colon cancer samples were dated 2002, while the lung and ovarian cancer specimens were dated 2008. Each laboratory used the protocol that was routinely used for standard DNA and/or RNA extractions as reported in Supplemental [1](#MOESM1){ref-type=""}, [2](#MOESM1){ref-type=""} and [3](#MOESM1){ref-type=""}. Although interesting, it was technically not feasible to test the different extraction methods by the diagnostic laboratories. The homemade protocols for the extractions are referred to detailed references, while the commercial kits are referred to the manufacturer's manuals. Each nucleic acid extract was quantified by means of Nanodrop (ThermoScientific). The total amount of nucleic acids and A~260~/A~280~ results were recorded for each extract. The quality assessment for DNA extracts was performed by the use of the BIOMED-2 control gene PCR method as previously described \[[@CR3]\]. This method is based on a multiplex PCR resulting in a ladder of fragments (100, 200, 300, and 400 bp) to check the quality and amplifiability of DNA from FFPE materials.

In detail, the undiluted DNA sample and 100 ng of the sample were amplified. In case no amplified band was detected (like the colon and lung specimens from participant 1), multiple DNA concentrations (10, 50, 200 ng) were amplified as well. The BIOMED-2 control gene PCR was run for all samples in one laboratory (Molecular Pathology, RUNMC, Nijmegen) and analyzed by electrophoresis on agarose gel.

For the first control round, RNA (colon cancer specimen) quality assessment by RT-PCR was performed in each laboratory using their routinely method with their usual fragment length amplification. All the protocols were based on DNA digestion and cDNA synthesis by the use of the random priming approach. In the second control round, for RNA extracts, DNase treatments and cDNA synthesis were all performed in one lab (Trieste), as previously reported \[[@CR4]\], after re-quantification of RNA. Complementary DNAs were then submitted in dry ice to Munich (LMU) for PCR analysis as described hereafter. Quality test for RNA was performed by amplifying different fragments of PBGD (Porphobilinogen deaminase) (150 and 250 bases), B2M (Beta-2-microglobulin) (200 bases) and β-actin (103 bases) housekeeping genes. As negative control, pure DNAse treated RNAs of a representative number of samples were used in the PCR reactions for specificity testing. Because the ovarian cancer samples yielded by far the lowest amount of RNA and neither PBGD nor B2M was detectable by PCR subsequent to standard reverse transcription procedure using random primer, these RNA samples were reverse transcribed using a PCR-target specific primer (β-actin forward, see below). The β-actin specific cDNA was amplified by PCR resulting in an amplification product of 103 bases. PCR products were analysed by agarose gel electrophoresis (3% w/v). For all PCR reactions, 200 ng cDNA (50 ng control cDNA, cell line) and the AmpliTaq Gold DNA polymerase (Applied Biosystems, Darmstadt, Germany) were used with 40 amplification cycles (10 min. 94°C; 40 cycles of 30 sec. 94°C, 30 sec. 60°C, 1 min. 72°C and one cycle 10 min. 72°C). For the β-actin and PBGD (250 bp amplicon) specific PCR, 1.5 mM MgCl~2~ and 0.2 mM dNTP-mix were used. The 150 bp amplicon PBGD-PCR employed 2.0 mM MgCl~2~ and the B2M specific PCR (200 bp) 2.5 mM MgCl~2~. The primer sequences were as follows:

PBGD (250 bp): forward: 5′-CTGGTAACGGCAATGCGGCT-3′, reverse: 5′-TTCTTCTCCAGGG CATGTTC-3′; PBGD (150 bp): forward: 5′-TGCCAGAGAAGAGTGTGGTG-3′, reverse: 5′-AT GATGGCACTGAACTCCTG-3′; B2M (200 bp): forward: 5′-GTTGACTTACTGAAGAATGG AG-3′, reverse: 5′-GATGCTGCTTACATGTCTCG-3′; β-actin (103 bp): forward: 5′-TTGCGGAT GTCCACGTCA-3′, reverse: 5′-GCCCTGAGGCACTCTTCCA-3′

Results {#Sec3}
=======

DNA {#Sec4}
---

Thirteen European participants were involved in the validation testing of DNA. The laboratories originating in Austria, Croatia, Germany, Italy, Portugal, Spain, Switzerland and The Netherlands were kept anonymous and were ranked according to the protocol type. The methods used by each participant were divided into 3 major groups, since the protocols within each group were similar. DNA extraction with precipitation of the DNA either by NaAc/EtOH (Participants 1, 2, 5) or by isopropanol (Participants 3, 4). Participant 4 took part only in the second round of DNA validation (lung and ovary cancer specimens).DNA extraction without further precipitation or purification (Participants: 6, 7 and 8, the latter only for the colon cancer sample)DNA extraction using silica based adsorption columns for purifying DNA (Participants: 9, 10, 11, 12 and 13).

Details on the used protocols are provided in Supplemental Tables [1](#MOESM1){ref-type=""} and [2](#MOESM1){ref-type=""}. The criteria used for evaluation of the DNA extracts were: 1) the DNA yield obtained by the extraction and 2) the DNA quality assessed by the purity measured by spectral-photometry (A~260~/A~280~) and by BIOMED-2 gene control PCR to test PCR-amplifiability. The median amounts of extracted DNA for each sample are reported in detail in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}, and show that the total amount of DNA extracted was highly dependent on the method used. The highest DNA-yields were obtained by the use of homemade methods that do not employ further purification of the DNA (Table [1](#Tab1){ref-type="table"}, protocol type 2). Note that in these DNA extracts, the measured concentration does not reflect the actual DNA quantity because of the co-presence of RNA and proteins debris, as it is apparent from the A~260~/A~280~ ratio (Supplemental Table [1](#MOESM1){ref-type=""}). Thus, the DNA yield and concentration of these specimens are only indicative. A lower DNA yield was obtained when using column based methods or homemade methods including a DNA precipitation step. This trend was shown for all the analyzed specimens. Table 1Results on the nucleic acids extraction quantitiesDNA yield by protocol typeRNA yield by protocol typeSampleProtocols type 1Protocols type 2Protocols type 3Protocols type 4Protocol type 5Protocols type 6Colon ca.72.8 µg (70-80)237 µg (145-274)46.5 µg (39-76)19.5 µg (17-22)38.4 µg (30-47)48.4 µg (12-70)Ovarian ca.17.4 µg (11-26)85.8 µg (70-101)8.1 µg (4-9)1.8 µg (1.5-4.9)2.6 µg (1.6-3.6)5.7 µg (2.5-6.8)Lung ca 135.1 µg (27-51)144 µg (125-163)15.6 µg (16-19)9.2 µg (5-22)41.0 µg (37-45)32.3 µg (8-41)Lung ca. 225.9 µg (16-37)160 µg (134-186)16.9 µg (15-19)8.9 µg (6-9)20.8 µg (19-23)22.9 µg (7-40)For each sample the median amount of extracted nucleic acid and the 25th and 75th centiles (in brackets) with respect of the protocol type are reported.Fig. 1Bar graph representing the total amount of extracted DNA from colon cancer, ovarian cancer and lung cancer (2) specimens by the use of different protocol types. Light grey bars are referred to protocol type 1 (DNA extraction with precipitation step); medium grey bars are referred to protocol type 2 (DNA extraction without purifications steps) and dark grey bars are referred to protocol type 3 (DNA extraction with commercial kits based on the use of silica based columns)

Differences in the purity of the DNA extracts hardly affect the PCR-amplifiability (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). The quality of the DNA extracted from the lung specimens allowed amplification of the 300 bp band of the control gene PCR for all protocols. Some protocols allowed amplification of the 400 bp fragment, although this band was only faintly detected. For the colon sample, many protocols allowed DNA-amplification of the 200 bp band as the maximal amplifiable length, while two homemade protocols only successfully amplified the smallest sized control amplicon of 100 bp. From one participant using a homemade protocol, DNA extracts from colon and lung specimens did not allow amplification of the control genes. Regarding the DNA extraction procedures characterised by purification steps, it seems there is no clear correlation among quantities of detected DNA and PCR performance; even for low amounts of extracted DNA the PCR performance was good. Table 2Performance of the extracted DNAs in the BIOMED-2 gene control PCRProtocol TypeParticipantColon Ca.Ovarian Ca.Lung Ca. 1Lung Ca. 211020000122001004003001310010030030014nd10030030015200100400400262001004003002720010040040038^a^10010040030039200100400300310200100300400311200100300300312nd100300300313nd100400300The performance is expressed in base pairs referred to the longest PCR fragment that was amplified. The 400 bp band, when detected, was only weakly present.nd= not determined, these participants (4, 12 and 13) did not send their DNA samples for general quality control testing.^a^ This participant used protocol type 2 for the colon cancer sample, as underlined.Fig. 2BIOMED-2 control gene PCR results of the extracted DNAs in duplicate of group 9, 6 and 2 (protocol type 3, 2 and 1 respectively). DNA was extracted from ovary (**a**), lung 1 (**b**) and lung 2 (**c**). The size of the amplified products is indicated. The lowest thick band represents primer-dimer products

RNA {#Sec5}
---

The validation of RNA isolation methods was performed by 10 participants from 8 European countries (Austria, Germany, Croatia, Italy, Portugal, Spain, Switzerland and The Netherlands). The participants were kept anonymous using the numbering of the DNA validation tests. The extraction protocols can be divided into 3 major groups as follows (numbered sequentially according to DNA protocols): RNA extraction using phenol extraction and isopropanol precipitation- homemade protocols (Participants 2, 4, 5)RNA extraction using phenol extraction and isopropanol precipitation- commercial mono-phase solutions (Participants 8, 11)RNA extraction using silica based columns for purification (Participants: 3, 4 only for Colon Cancer sample, 6, 7, 9, 12)

The criteria for assessing the quality of the RNA isolation method were: 1) the RNA yield and 2) the RNA quality determined by purity detection using spectral-photometry (A~260~/A~280~) and by amplification methods. The RNA was isolated from a single case of colorectal cancer, two lung cancer cases and one ovary cancer tissue. The median amount of extracted RNA is reported in Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}. Regarding the protocol type, the RNA yield was higher with the use of commercial kits based on silica column purification (protocol type 6), followed by the use of commercial solutions and the homemade protocols. The Qiagen RNeasy FFPE kit using an extended proteinase-K digestion time revealed the best performance regarding the yield (Supplemental Table [4](#MOESM1){ref-type=""}). However, when the Qiagen RNeasy FFPE kit was used by different participants, remarkable differences in RNA yield were observed (Supplemental Tables [3](#MOESM1){ref-type=""} and [4](#MOESM1){ref-type=""}, Fig. 3 participant 12 vs. 7). Fig. 3Bar graph representing the total amount of extracted RNA from colon cancer, ovarian cancer and lung cancer (2) specimens by the use of different protocol types. Light grey bars are referred to protocol type 4 (RNA extraction with home-made protocols); medium grey bars are referred to protocol type 5 (RNA extraction with monophasic commercial solutions) and dark grey bars are referred to protocol type 6 (RNA extraction with commercial kits based on the use of silica based columns)

The RNA quality was measured by RNA purity detection using spectral-photometry (A~260~/A~280~). The highest purity was obtained by silica based column purification procedures (protocol type 6) (Qiagen RNeasy FFPE kit and Roche High Pure RNA Paraffin kit) with the exception of the Gentra kit and was followed by the homemade protocol (protocol type 4) based on phenol extraction and isopropanol precipitation. The commercial solution method (protocol type 5) gained the least pure RNA measured by the A~260~/A~280~ absorption ratio. To further validate the RNA quality a standardized PCR procedure was used with four different amplicon lengths (103 bp, 150 bp, 200 bp, 250 bp) after standard reverse transcription. The original RNA of the samples was used as negative control resulting in no PCR product. Taken together, the column based commercial kits (protocol type 6 - Qiagen RNeasy FFPE kit and Roche High Pure RNA Paraffin kit) yielded the best assayable RNA quality (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Interestingly the performance of the RNA in the RT-PCR reaction did not always correlate with RNA purity data, as RNA obtained by commercial solutions with the least pure RNA (protocol type 5) performed better than RNA extracted by homemade protocols (protocol type 4; see Table [3](#Tab3){ref-type="table"}). Table 3Results on RNA quality assessment by PCRProtocol TypeParticipantColon Ca^a^Ovarian CaLung Ca. 1Lung Ca. 24215010320020044^b^[200]{.ul}1032002004516010320020058127103-25051125010325020063160103150-661851032502506720010325025069110103\--612293103250250Results are expressed in base pairs referred to the longest amplifiable PCR product.The larger the PCR product, the better the RNA quality was considered.^a^ no PCR for longer amplicon was performed in the first round of testing; the analysed housekeeping genes were: ACTB (Beta-Actin), PBGD (Porphobilinogen deaminase), PDHB (Pyruvate dehydrogenase, beta), GUSB (Glucuronidase, beta), FGFR3 (Fibroblast growth factor receptor 3).^b^ This participant used for colon cancer specimen the protocol type 6, as underlined.(-) no PCR product was obtained (150 bp or larger amplicons).Fig. 4B2M housekeeping gene specific RT-PCR results of the extracted RNAs of the group 2, 11, 6, 3, 7 and 12 (protocol type 4, 5 and four times 6, respectively). RNA was extracted from ovary (**a**), lung 1 (**b**) and lung 2 (**c**). The PCR products were separated in 3 % (w/v) agarose gels. The size of the amplification products is indicated (200 bp). M: size marker (50 bp DNA Ladder, Invitrogen, Karlsruhe, Germany)

Discussion {#Sec6}
==========

Diagnostic methodologies need per definition a basic level of standardization in order to obtain concordance in the responses among hospitals. Immunohistochemistry (IHC) is the most widely used method to detect proteins in FFPE tissues for diagnostic purposes. Despite the standardization of immunohistochemical staining protocols, some factors could still vary among samples and laboratories, such as tissue fixation (duration), choice of antibodies, and the threshold for interpretation of positive immunostaining, which may dramatically affect test accuracy and reproducibility. In any case IHC is considered an accurate diagnostic method because there are guidelines and inter-laboratory quality controls through the cross-testing of cases that guarantee the reliability of the assays. Nowadays, there is great interest and need for molecular pathology tests in order to better characterize pathologies and better define the individual patient profile for tailored therapy. In the present study, we have systematically compared the results of different homemade and commercial protocols for DNA and RNA extraction on the same set of FFPE tissue specimens used in several laboratories in order to define reliable criteria on nucleic acid extraction from FFPE tissues.

The design of this multicentre study allows determining the specific effects of the different extraction protocols, since the quality control experiments and interpretation of the multicentric results were performed in a single laboratory. Nonetheless, we cannot entirely exclude the possible effects of additional parameters, such as different technicians and laboratory equipments, which may influence the results. However, as the extractions were performed by experienced technicians in molecular diagnostic laboratories, we anticipate a minimal effect of these parameters.

The FFPE tissues used in this study originate from routine diagnostics of three different pathology departments. Hence it may well be possible that fixation time and the size of the tissue pieces used, which is important for the fixation rate, varies. Formalin not only cross-links proteins and nucleic acids, it also modifies RNA by adding mono-methylol groups to all the four bases blocking reverse transcription \[[@CR5]\]. However it has been shown that the efficiency of extracting amplifiable RNA and DNA from FFPE tissue is inversely proportional to the fixation time \[[@CR6], [@CR7]\] and thus standardized fixation conditions are important. This was not specifically addressed in the current study since all laboratories used serial sections of the same tissue block of each cancer tissue.

DNA {#Sec7}
---

DNA extraction protocols that used purification of the extracted DNA, either by precipitation (protocol type 1) or by using silica-based columns (protocol type 3) gave comparable results in terms of yield and purity of the DNA. The apparent yield of DNA by the use of these protocols is less comparable to protocols that do not employ any purification (protocol type 2), which is not surprising, since the measured DNA-concentration in the un-purified samples reflects the presence of RNA and DNA. Yield and concentration from protocols that do not employ purification steps is thus not accurate since degraded RNAs as well as protein debris are also quantified, overestimating thereby the real DNA amount.

The PCR-amplifiability of the DNA samples was not drastically affected by the use of different DNA-extraction protocols. Our study showed that the measurement of amplify-ability of the DNA by performance of the BIOMED-2 control gene PCR is the preferred parameter, superior to spectrophotometrical determination of the A~260~/A~280~ ratio, to measure DNA-quality for diagnostic molecular testing. In general, DNA obtained from FFPE samples that allows amplification of 300 bp is considered as good DNA-quality and can be used for many molecular tests, including clonality testing using the BIOMED-2 primers and protocols \[[@CR8]\]. Array comparative genomic hybridization (aCGH) was successful using DNA samples from FFPE tissues, which allowed amplifying 200 bp in the BIOMED-2 control gene PCR \[[@CR9]\]. Based on evaluation of the DNA-amplifyability, there is not a single DNA-extraction protocol that is highly superior to others. The majority of the DNA-extraction protocols, except for the DNA-extraction protocol by participant 1, give similar and comparable results. There was only a minor difference in outcome, showing less performance of the DNA-extraction protocol used by participants 3 and 8a. However, as this was seen only in one of the four tested samples, there is no solid reason to avoid the use of these protocols.

Upon selection of the protocol to use in a diagnostic laboratory, also the requirements for the specific molecular test should be taken into consideration. It should be realised that molecular tests that require a standardized input of DNA, should use purified DNA-samples, allowing the most accurate DNA-quantification. For complex multiplexed PCRs or tests that require a specific accurate input of DNA per PCR test, like B- /T-cell clonality assessment, \[[@CR8]\], as well as for application of array-CGH \[[@CR6]\], MLPA-based tests \[[@CR7]\], we strongly recommend using type 3 protocols that use silica based adsorption columns for purifying DNA.

For other molecular tests like PCR followed by direct sequencing, however, purification may not be essential. The use of protocols without further purification (protocol type 2) has an additional advantage, it is more rapid and less expensive compared to DNA-protocols that employ purification steps. We therefore recommend the use of a simple DNA-protocol, such as the type 2 protocols (DNA extractions without further purification or precipitation), for general molecular tests as mutation and translocation detection. Whichever the method used, it is highly recommended to employ only optimized and controlled reagents. This can be an important source of result variability.

RNA {#Sec8}
---

The RNA isolation methods affected the yield of the extracted RNA, even when extraction conditions (proteinase K incubation time and temperature) were comparable (Supplemental Table [3](#MOESM1){ref-type=""}). Proteinase K digestion is an important step affecting the RNA yield. In fact, we observed that an extended digestion time resulted in a more efficient extraction, especially from colon and ovarian tumour tissue using the Qiagen RNeasy FFPE kit. This is consistent with previous reports demonstrating that increasing proteinase K digestion time improved the RNA yield \[[@CR6], [@CR10], [@CR11]\]. Formalin fixation preserves cellular structures by crosslinking biomolecules and thus traps nucleic acids and prevents the extraction of amplifiable RNA and DNA. By extending the digestion time to at least 16 hours, proteinase K is thought to release protein cross-linked nucleic acids more efficiently to permit subsequent RNA/DNA isolation, e.g. by column based methods \[[@CR6]\]. Surprisingly, extended proteinase K incubation had no effect on the RNA quality evaluated by RT-PCR.

The RNA quality assessment by spectral photometry did not correlate with the maximum amplifiable length (Tables [1](#Tab1){ref-type="table"} and [3](#Tab3){ref-type="table"}). The ratio A~260/280~ is an indicator of possible contaminants \[[@CR12]\] and the presence of inhibitors for subsequent reactions, however, this measurement is highly variable \[[@CR13]\] and does not assess the length of the RNA extracted. Similarly, the widely used quality assessment by capillary electrophoresis (Bioanalyzer or Experion) is not predictive of the utility of RNA samples isolated from FFPE tissue in molecular analyses, since the most limiting factor for RT-PCR and presumably other enzymatic procedures, is the chemical modification of RNA by formaldehyde, which is not resolved by electrophoretic assays \[[@CR10], [@CR14]\].

Regarding the high degree of degradation of RNA in FFPE tissues, the ability of amplifying 250 bp PCR-fragments indicates RNA of very good quality. Nevertheless, the successful amplification of target mRNA fragments ≥200 bp in length was considered good RNA quality \[[@CR11], [@CR15]\]. All isolation methods resulted in RNA of useful quality for expression analyses in archival and diagnostic tissues, since shorter amplicons are sufficient for quantitative PCR \[[@CR15]--[@CR17]\]. This study reveals that column based methods (protocol type 6) provided best RNA quality assessed by RT-PCR from most of the tissues. Moreover these methods, in comparison to homemade protocols and commercial monophasic solutions, are less time-consuming by omitting the precipitation step to isolate the RNA. Small adjustments of the manufacturer's instruction (e.g. proteinase K digestion) may have caused inter-laboratory variability both in RNA quantity and quality, which is consistent with earlier reports demonstrating that different results were obtained by different groups using the same commercial kits \[[@CR10], [@CR15]\].

Although homemade RNA extraction methods (protocol type 4) or commercial solutions (protocol type 5) may be suitable for certain applications in research and diagnostics using short amplicons (below 160 bp), our results demonstrate that among the analyzed methods , particularly the Qiagen RNeasy FFPE kit including an extended proteinase-K digestion period is recommended. Due to the observed inter-laboratory variability, further standardization of the techniques, including commercial kits, is recommended for research and diagnostic applications in molecular pathology.
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